Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus SODIUM ROSE BENGAL I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus SODIUM ROSE BENGAL I 131.
CIS-MDP vs SODIUM ROSE BENGAL I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Sodium rose bengal I 131 is a radioactive diagnostic agent that is taken up by hepatocytes and excreted into the bile, allowing imaging of the hepatobiliary system. The radioactive iodine (I-131) emits gamma rays, which can be detected externally to assess liver and gallbladder function.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
5-50 µCi (0.185-1.85 MBq) intravenous bolus for hepatic function imaging. For functional imaging of hepatobiliary system, typical dose: 150-300 µCi (5.55-11.1 MBq) IV.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life is approximately 3-7 days, reflecting slow clearance from the liver and bile.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Primarily hepatic excretion into bile (90-95%), with minimal renal excretion (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical